S&P 500   3,115.44 (+0.61%)
DOW   27,943.53 (+0.58%)
QQQ   202.64 (+0.60%)
CGC   15.36 (-3.03%)
BABA   185.29 (+1.36%)
GE   11.51 (+1.95%)
T   39.33 (+0.98%)
ACB   3.01 (-8.80%)
F   8.94 (+1.71%)
PRI   131.00 (+0.61%)
BAC   32.93 (+0.67%)
DIS   145.12 (-1.38%)
S&P 500   3,115.44 (+0.61%)
DOW   27,943.53 (+0.58%)
QQQ   202.64 (+0.60%)
CGC   15.36 (-3.03%)
BABA   185.29 (+1.36%)
GE   11.51 (+1.95%)
T   39.33 (+0.98%)
ACB   3.01 (-8.80%)
F   8.94 (+1.71%)
PRI   131.00 (+0.61%)
BAC   32.93 (+0.67%)
DIS   145.12 (-1.38%)
S&P 500   3,115.44 (+0.61%)
DOW   27,943.53 (+0.58%)
QQQ   202.64 (+0.60%)
CGC   15.36 (-3.03%)
BABA   185.29 (+1.36%)
GE   11.51 (+1.95%)
T   39.33 (+0.98%)
ACB   3.01 (-8.80%)
F   8.94 (+1.71%)
PRI   131.00 (+0.61%)
BAC   32.93 (+0.67%)
DIS   145.12 (-1.38%)
S&P 500   3,115.44 (+0.61%)
DOW   27,943.53 (+0.58%)
QQQ   202.64 (+0.60%)
CGC   15.36 (-3.03%)
BABA   185.29 (+1.36%)
GE   11.51 (+1.95%)
T   39.33 (+0.98%)
ACB   3.01 (-8.80%)
F   8.94 (+1.71%)
PRI   131.00 (+0.61%)
BAC   32.93 (+0.67%)
DIS   145.12 (-1.38%)
Log in

Alimera Sciences Stock Price, Forecast & Analysis (NASDAQ:ALIM)

$4.84
+4.53 (+1,461.29 %)
(As of 11/15/2019 12:41 PM ET)
Today's Range
$4.62
Now: $4.84
$5.20
50-Day Range
$0.21
MA: $0.38
$0.57
52-Week Range
$0.20
Now: $4.84
$1.21
Volume4,326 shs
Average Volume1.00 million shs
Market Capitalization$360.34 million
P/E RatioN/A
Dividend YieldN/A
Beta1.89
Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALIM
CUSIPN/A
Phone678-990-5740

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$46.97 million
Book Value($0.49) per share

Profitability

Net Income$-16,380,000.00

Miscellaneous

Employees124
Market Cap$360.34 million
Next Earnings Date2/4/2020 (Estimated)
OptionableOptionable

Receive ALIM News and Ratings via Email

Sign-up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter.


Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions

What is Alimera Sciences' stock symbol?

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

When did Alimera Sciences' stock split? How did Alimera Sciences' stock split work?

Shares of Alimera Sciences reverse split before market open on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of Alimera Sciences stock prior to the reverse split would have 7 shares after the split.

How were Alimera Sciences' earnings last quarter?

Alimera Sciences Inc (NASDAQ:ALIM) posted its quarterly earnings data on Tuesday, October, 29th. The biopharmaceutical company reported ($0.60) EPS for the quarter, meeting analysts' consensus estimates of ($0.60). The biopharmaceutical company had revenue of $12.85 million for the quarter, compared to the consensus estimate of $12.75 million. View Alimera Sciences' Earnings History.

When is Alimera Sciences' next earnings date?

Alimera Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Alimera Sciences.

What guidance has Alimera Sciences issued on next quarter's earnings?

Alimera Sciences updated its third quarter 2019 earnings guidance on Wednesday, October, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $12.8 million, compared to the consensus revenue estimate of $12.87 million.

What price target have analysts set for ALIM?

3 brokerages have issued 1 year price targets for Alimera Sciences' shares. Their forecasts range from $15.00 to $45.00. On average, they expect Alimera Sciences' stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 519.8% from the stock's current price. View Analyst Price Targets for Alimera Sciences.

What is the consensus analysts' recommendation for Alimera Sciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alimera Sciences.

Has Alimera Sciences been receiving favorable news coverage?

News stories about ALIM stock have been trending somewhat negative recently, InfoTrie reports. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Alimera Sciences earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Alimera Sciences.

Are investors shorting Alimera Sciences?

Alimera Sciences saw a drop in short interest during the month of October. As of October 31st, there was short interest totalling 996,200 shares, a drop of 29.8% from the September 30th total of 1,420,000 shares. Based on an average daily trading volume, of 493,600 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.7% of the company's shares are sold short. View Alimera Sciences' Current Options Chain.

Who are some of Alimera Sciences' key competitors?

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include Eyepoint Pharmaceuticals (EYPT), NovaBay Pharmaceuticals (NBY), Agenus (AGEN), Athersys (ATHX), Novavax (NVAX), CorMedix (CRMD), Adamis Pharmaceuticals (ADMP), Aldeyra Therapeutics (ALDX), Amarin (AMRN) and BIOLINERX LTD/S (BLRX).

Who are Alimera Sciences' key executives?

Alimera Sciences' management team includes the folowing people:
  • Mr. Charles Daniel Myers, Non-Exec. Chairman & Consultant (Age 65)
  • Mr. Richard S. Eiswirth Jr., Pres, CEO & Director (Age 51)
  • Dr. Kenneth Green, Consultant (Age 61)
  • Mr. David R. Holland, Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets (Age 55)
  • Mr. J. Philip Jones, Chief Financial Officer (Age 55)

How do I buy shares of Alimera Sciences?

Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alimera Sciences' stock price today?

One share of ALIM stock can currently be purchased for approximately $4.84.

How big of a company is Alimera Sciences?

Alimera Sciences has a market capitalization of $360.34 million and generates $46.97 million in revenue each year. Alimera Sciences employs 124 workers across the globe.View Additional Information About Alimera Sciences.

What is Alimera Sciences' official website?

The official website for Alimera Sciences is http://www.alimerasciences.com/.

How can I contact Alimera Sciences?

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]


MarketBeat Community Rating for Alimera Sciences (NASDAQ ALIM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  302 (Vote Outperform)
Underperform Votes:  298 (Vote Underperform)
Total Votes:  600
MarketBeat's community ratings are surveys of what our community members think about Alimera Sciences and other stocks. Vote "Outperform" if you believe ALIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel